Cidara Therapeutics (CDTX) AI Stock Analysis

• Market Cap: $230.02M
• Dividend Yield: N/A
• Average Volume (3M): 97.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: -86.28%
• EPS Growth: -476.70%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -29.69
• Shares Outstanding: 10,953,490
• 10 Day Avg. Volume: 105,843
• 30 Day Avg. Volume: 97,771
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 9.31
• Price to Cash Flow (P/CF): -1.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $37.50
• Price Target Upside: 78.57% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Cidara Therapeutics demonstrates strong technical indicators, suggesting potential short-term trading opportunities. However, its financial performance is notably weak, with persistent losses and reliance on external financing. The valuation is concerning due to the negative P/E ratio, reflecting ongoing profitability challenges. These factors result in a moderate overall score, indicating the need for cautious optimism regarding future performance.

Positive Factors

Clinical Trial Success

CD388 successfully achieved the study's primary efficacy endpoint with a statistically significant reduction in nasal viral load vs. placebo.

Innovative Technology

Cidara's novel platform technology has the potential to transform the influenza therapeutic landscape, pointing to a billion-dollar opportunity.

Negative Factors

Dependency on Clinical Trials

The Ph2b NA VIGATE Flu prevention trial of CD388 was initiated, and results are anticipated to be available in 3Q25.

Cidara Therapeutics Business Overview & Revenue Model

Company Description

Cidara Therapeutics (CDTX) is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. The company primarily operates in the pharmaceutical and healthcare sectors, with a core focus on developing long-acting therapeutics designed to improve the standard of care for patients facing serious infections and oncology treatments.

How the Company Makes Money

Cidara Therapeutics generates revenue through a combination of product sales, licensing agreements, and collaborative partnerships. The company earns money by developing and commercializing its drug candidates, particularly its lead product candidates in the areas of antifungal and antiviral treatments. Cidara enters into strategic partnerships with larger pharmaceutical companies to co-develop and market its products, which provides milestone payments and royalties as sources of income. Additionally, the company's collaborations often include research and development funding to advance its pipeline of innovative therapies. These partnerships and licensing agreements are significant factors contributing to Cidara's earnings, allowing it to leverage external resources and expertise to bring its products to market.

Cidara Therapeutics Financial Statement Overview

Summary

Overall, Cidara Therapeutics faces significant financial challenges with persistent losses and negative cash flows. While the balance sheet shows low leverage, the company relies heavily on external financing to fund operations. The biotechnology industry often requires long-term investment before profitability, yet the current financial trajectory suggests a need for strategic improvements to ensure sustainability.

Income Statement

Cidara Therapeutics has experienced a significant revenue decline in the latest year, with a revenue growth rate of -98% from the previous year. The net profit margin is deeply negative, at -13362.04% for 2024, indicating substantial losses relative to revenue. The gross profit margin is also negative, suggesting that the company is selling below cost. While biotechnology companies often face high R&D expenses, the magnitude of losses is concerning.

Balance Sheet

The company's debt-to-equity ratio is low due to a relatively high stockholders' equity, indicating low leverage. However, the equity ratio is 76.02%, reflecting a stable capital structure. Despite this, the company has historically negative equity, raising concerns about sustainable financial health. The increase in cash reserves provides some liquidity cushion.

Cash Flow

Operating cash flow is significantly negative, although there has been substantial cash inflow from financing activities. Free cash flow remains negative, and the operating cash flow to net income ratio is negative, due to both operating cash flow and net income being negative. The company is heavily dependent on external financing to sustain operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.27M	63.91M	64.29M	49.57M	12.07M
	Gross Profit
-83.61M	62.38M	64.14M	49.38M	-55.95M
	EBIT
-176.10M	-24.48M	-29.72M	-42.26M	-71.85M
	EBITDA
-176.10M	-24.36M	-33.36M	-42.26M	-71.56M
	Net Income Common Stockholders
-169.83M	-22.93M	-29.80M	-43.91M	-72.37M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
189.82M	35.78M	32.73M	62.27M	35.91M
	Total Assets
214.80M	67.03M	47.59M	75.33M	60.42M
	Total Debt
3.58M	4.88M	1.32M	5.06M	7.96M
	Net Debt
-186.25M	-30.90M	-31.41M	-57.21M	-27.95M
	Total Liabilities
51.49M	75.24M	50.50M	53.75M	49.71M
	Stockholders Equity
163.31M	-8.21M	-2.90M	21.57M	10.71M
Cash Flow		Free Cash Flow
-176.66M	-22.94M	-28.59M	-25.27M	-54.60M
	Operating Cash Flow
-176.53M	-22.43M	-28.47M	-25.23M	-54.41M
	Investing Cash Flow
-129.00K	-505.00K	-118.00K	-41.00K	-186.00K
	Financing Cash Flow
337.06M	25.98M	-951.00K	44.60M	37.28M

Cidara Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CDTX, the sentiment is Positive. The current price of 21 is below the 20-day moving average (MA) of 22.93, below the 50-day MA of 22.38, and above the 200-day MA of 15.81, indicating a bullish trend. The MACD of 0.27 indicates Positive momentum. The RSI at 52.46 is Neutral, neither overbought nor oversold. The STOCH value of 29.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CDTX.

Cidara Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANIP	65 Neutral	$1.34B	―	-4.86%	―	26.20%	-219.22%
AKBA	53 Neutral	$421.09M	―	91.25%	―	-12.26%	32.86%
CDTX	51 Neutral	$230.02M	―	-222.36%	―	-86.28%	-476.70%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
BCRX	44 Neutral	$1.58B	―	18.68%	―	36.00%	63.50%
XOMA	42 Neutral	$241.55M	―	-31.41%	―	389.82%	-22.66%
VTGN	42 Neutral	$76.63M	―	-46.28%	―	-33.00%	54.91%

Cidara Therapeutics Corporate Events

Cidara Therapeutics Announces CFO Transition

Cidara Therapeutics announced that its Chief Financial Officer, Dr. Preetam Shah, will be leaving the company effective February 24, 2025, with Frank Karbe appointed as his successor. Dr. Shah’s departure is part of a mutual agreement, and he will serve as a consultant for six months post-departure, while Mr. Karbe joins with a robust background in finance and leadership roles in biopharmaceutical companies, potentially strengthening Cidara’s financial strategy and industry positioning.

Cidara Therapeutics Announces Leadership Changes and Appointments

Cidara Therapeutics announced key leadership changes with the resignation of board member Laura Tadvalkar, Ph.D., and the mutual separation of Chief Medical Officer Taylor Sandison, M.D., M.P.H., to be effective on February 3, 2025. Nicole Davarpanah, M.D., J.D., will assume interim Chief Medical Officer responsibilities. Additionally, Josh Resnick, M.D., was appointed as a Class II board member, with his term expiring at the 2026 annual stockholder meeting. His compensation package includes an annual cash retainer and stock option grants, underlining Cidara’s commitment to strengthen its governance and strategic direction.